应用药物铺灸疗法辨证治疗痛风病78例临床观察

目的:研究应用药物辅灸疗法辨证治疗痛风病的临床疗效。方法:选取2015年1月至2016年12月期间秦皇岛市中医医院收治的痛风患者78例作为研究对象,根据随机数表法分为对照组、观察组,各39例。对照组患者采用秋水仙碱等对症治疗,观察组患者采用药物辅灸疗法辨证治疗,持续治疗2周,后给予患者1~3个月随访。比较2组患者治疗前后疼痛程度变化及治疗后血肌酐(Cre)、血尿素氮(BUN)、尿酸(UA)水平、生命质量。结果:治疗后,2组患者疼痛VAS评分均低于治疗前,且观察组低于对照组,差异有统计学意义(P0.05);观察组患者的Cre、BUN、UA水平均低于对照组,差异有统计学意义(P0.05);观察组患者社会功能、生理功能、健康自我认识、心理功能评分均高于对照组,差异有统计学意义(P0.05)。结论:应用药物辅灸疗法辨证治疗痛风病效果显著,能有效减轻患者疼痛程度,调节血清Cre、BUN、UA水平,缓解临床症状与体征,改善患者生命质量。

Clinical Observation on 78 Cases of Gout Treated by Drug Assisted Moxibustion Therapy

To study the clinical efficacy of syndrome differentiation treatment of gout with drug assisted moxibustion therapy. Methods:A total of 78 cases of gout patients from January 2015 to December 2016 in our hospital for treatment were selected as the object of study. The patients were divided into control group and study group according to the random number table method, with 39 cases in each group. The patients in the control group were treated with colchicine. The patients in the study group were treated with drug-assisted moxibustion therapy for 2 weeks. The patients were followed up for 1-3 months. The levels of serum creatinine (Cre), blood urea nitrogen (BUN), uric acid (UA) and quality of life were compared between the two groups before and after treatment. Results:After treatment, the VAS scores of the two groups were lower than those before treatment, and the study group was lower than the control group. The difference was statistically significant (P<0.05). The levels of Cre, BUN and UA in the study group were lower than those in the control group, and the difference was statistically significant (P<0.05). The scores of social function, physiological function, healthy self-cognition and psychological function of the study group were higher than those of the control group, and the difference was statistically significant (P<0.05). Conclusion:Drug-assisted moxibustion therapy based on syndrome differentiation treatment of gout has significant effects, and can effectively reduce the degree of pain in patients with regulation of serum Cre, BUN, UA levels, relieving clinical symptoms and signs and improving patient quality of life.